Ep 74: Best of ESMO 2025: Part 2 of 2

SummaryIn this Part 2 Best of ESMO 2025 episode of Melanoma Matters, hosts James Larkin and Sapna Patel cover the IO Biotech phase 3 trial, Checkmate 238 final results, the Safe Stop trial, the ECOG-ACRIN STAMP trial for Merkel cell carcinoma, and a promising TCR therapy for uveal melanoma. Keywordsmelanoma, cancer research, immunotherapy, clinical trials, ESMO, IO Biotech, Checkmate 238, Safe Stop trial, STAMP trial, uveal melanomaTakeawaysThe IO Biotech trial missed its primary endpoint for PFS.Checkmate 238 confirmed previous findings on RFS and DMFS.The Safe Stop trial suggests early discontinuation of therapy may be safe.STAMP trial shows potential for adjuvant pembrolizumab in Merkel cell carcinoma.Uveal melanoma TCR therapy shows promise.Understanding subgroup analysis in interpreting trial results.Patient management decisions should consider trial limitations and real-world implications.Chapters00:00 Travel Tips and Strategies04:43 IO Biotech Phase 3 Trial Insights12:00 Checkmate 238 Discussion13:10 Navigating Publication Challenges13:59 Checkmate 238 Results15:58 Late Relapses and Follow-Up Strategies17:57 Time of Day of Infusion20:50 Safe Stop Trial: Evaluating Treatment Duration33:12 STAMP Trial: Adjuvant Therapy for Merkel Cell Carcinoma35:05 IMA-203 (Anzu-cel) trial in uveal melanoma